Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Lamotrigine 100 mg Tablets
NCT03898011Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lamotrigine in epilepsy and bipolar disorder (BD) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Timepoint. Started Mar 2019; status: completed.
02
Drugs
lamotrigine
03
Conditions
epilepsybipolar disorder (BD)
Beyond the preview
Go deeper on NCT03898011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03898011.